Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Apr 21:2015:1203.

Parkinson's disease: fetal cell or stem cell-derived treatments

Arnar Astradsson  1 , Tipu Z Aziz
Affiliations

Parkinson's disease: fetal cell or stem cell-derived treatments

Arnar Astradsson et al. BMJ Clin Evid. .

Abstract

Introduction: The mean age of onset of Parkinson's disease is about 65 years, with a median time of 9 years between diagnosis and death.

Methods and outcomes: We conducted a systematic review and aimed to answer the following clinical question: What are the effects of fetal cell or stem cell-derived therapy in people with Parkinson's disease? We searched: Medline, Embase, The Cochrane Library and other important databases up to September 2014 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).

Results: We found two studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.

Conclusions: In this systematic review we present information relating to the effectiveness and safety of the following interventions: fetal cell therapy versus deep brain stimulation; fetal cell therapy versus sham surgery; stem cell-derived therapy versus deep brain stimulation; stem cell-derived therapy versus sham surgery.

PubMed Disclaimer

References

    1. Litvan I, Bhatia KP, Burn DJ, et al. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord 2003;18:467–486. - PubMed
    1. Taylor KS, Cook JA, Counsell CE. Heterogeneity in male to female risk for Parkinson's disease. J Neurol Neurosurg Psychiatry 2007;78:905–906. - PMC - PubMed
    1. Wooten GF, Currie LJ, Bovbjerg VE, et al., 2004. Are men at greater risk for Parkinson's disease than women? J Neurol Neurosurg Psychiatry 2004;75:637–639. - PMC - PubMed
    1. Zhang Z, Román G. Worldwide occurrence of Parkinson's disease: an updated review. Neuroepidemiology 1993;12:195–208. - PubMed
    1. De Rijk MC, Tzourio C, Breteler MM, et al. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON collaborative study. J Neurol Neurosurg Psychiatry 1997;62:10–15. - PMC - PubMed

Publication types